Lyra Therapeutics, Inc. (LYRA)
OTCMKTS · Delayed Price · Currency is USD
0.1900
-0.0050 (-2.56%)
At close: Oct 9, 2026
Lyra Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Enlightened II phase III trial of LYR-210 in CRS met primary and key secondary endpoints, showing significant symptom and quality-of-life improvements with a strong safety profile. Plans are underway for FDA engagement and further studies in polyp patients.